Dogecoin's transaction volume surged to nearly $800 million, the highest daily volume in 2026, driven by a rally in its price. The surge indicates increased retail activity and market interest in DOGE, with the price climbing amid broader crypto market movements. This highlights Dogecoin's growing popularity and trading activity this year.
RAVE token surged 138% after ZachXBT accused RaveDAO of a pump-and-dump scheme, with the price now between $0.619 and $0.646. Despite allegations, the token experienced a significant rebound, raising questions about market sentiment and on-chain data. The event highlights ongoing concerns over manipulation in the crypto space, with traders closely watching for the next move.
Most XRP investors are now in profit as the cryptocurrency's price approaches a potential 55% breakout to $2.24. The key support level is $1.40, which bulls need to maintain to enable the rally. The current market sentiment suggests increased confidence among XRP holders, with the possibility of significant gains if the price sustains above critical levels.
Goldman Sachs CEO warns that ongoing Iran conflict could push oil prices to $170 per barrel, potentially straining global economies and increasing inflation. The rise in oil prices, if realized, could significantly impact energy policies and geopolitical stability. The statement highlights concerns over the economic repercussions of escalating tensions in Iran, with no specific date mentioned for the price surge.
Crypto presale platform TradeView introduces gasless trading and wallet access, aiming to improve user experience. As usability concerns hinder adoption, TradeView’s features target reducing friction in trading. The platform’s focus on infrastructure and ease of access positions it as a promising contender in the 2026 presale market, attracting traders seeking seamless crypto transactions.
Ripple moved $100 million in XRP on-chain as exchange reserves reached 2.76 billion tokens, with the price holding at $2.15. The move raises questions about potential market direction, with some analysts suggesting a possible dump while others believe bulls may defend the support level. The market remains cautious amid these developments.
Hims & Hers stock surged 49% over five days after FDA announced a July review for easing peptide restrictions, opening new revenue opportunities. The company’s partnership with Novo Nordisk and backing from RFK Jr. boosted investor confidence. The move signals potential growth in biotech and wellness sectors, driven by regulatory developments and strategic collaborations.
